U.S. Cell And Gene Therapy CDMO Market (2025 - 2033) Size, Share & Trends Analysis Report By Phase (Pre-clinical, Clinical), By Product (Gene Therapy, Cell Therapy, Gene-Modified Cell Therapy), By Indication (Oncology, Infectious Diseases), And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation and Scope
                    1.2. Market Definitions
                    1.3. Research Methodology
                    1.4. Information Procurement
                        1.4.1. Purchased database
                        1.4.2. GVR’s internal database
                        1.4.3. Secondary sources
                        1.4.4. Primary research
                    1.5. Information or Data Analysis
                        1.5.1. Data analysis models
                    1.6. Market Formulation & Validation
                    1.7. Model Details
                        1.7.1. Commodity flow analysis (Model 1)
                        1.7.2. Value chain based analysis (Model 2)
                        1.7.3. Multivariate Analysis (Model 3)
                    1.8. List of Secondary Sources
                    1.9. List of Primary Sources
                    1.10. Objectives
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Snapshot
                    2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Cell And Gene Therapy CDMO Market: Variables, Trends, & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent Market Outlook
                        3.1.2. Ancillary Market Outlook
                    3.2. U.S. Cell And Gene Therapy CDMO Market Dynamics
                        3.2.1. Market Driver Impact Analysis
                        3.2.2. Market Restraint Analysis
                    3.3. Technological Landscape
                    3.4. Pricing Model Analysis
                    3.5. U.S. Cell And Gene Therapy CDMO Market: Analysis Tools
                        3.5.1. Porter’s Five Forces Analysis
                        3.5.2. PESTEL Analysis
Chapter 4. U.S. Cell And Gene Therapy CDMO Market: Service Estimates & Trend Analysis
                    4.1. Segment Dashboard
                    4.2. U.S. Cell And Gene Therapy CDMO Market Phase Movement Analysis
                    4.3. U.S. Cell And Gene Therapy CDMO Market Size & Trend Analysis, by Phase, 2021 to 2033 (USD Million)
                    4.4. Pre-clinical
                        4.4.1. Pre-clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.5. Clinical
                        4.5.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. U.S. Cell And Gene Therapy CDMO Market: Product Estimates & Trend Analysis
                    5.1. Segment Dashboard
                    5.2. U.S. Cell And Gene Therapy CDMO Market Product Movement Analysis
                    5.3. U.S. Cell And Gene Therapy CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
                    5.4. Gene Therapy
                        5.4.1. Gene Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        5.4.2. Ex-vivo
                            5.4.2.1. Ex-vivo Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        5.4.3. In-vivo
                            5.4.3.1. In-vivo Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    5.5. Gene-Modified Cell Therapy
                        5.5.1. Gene-Modified Cell Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        5.5.2. CAR T-cell therapies
                            5.5.2.1. CAR T-cell therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        5.5.3. CAR-NK cell therapy
                            5.5.3.1. CAR-NK cell therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        5.5.4. TCR-T cell therapy
                            5.5.4.1. TCR-T cell therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        5.5.5. Other
                            5.5.5.1. Other Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    5.6. Cell Therapy
                        5.6.1. Cell Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. U.S. Cell And Gene Therapy CDMO Market: Indication Estimates & Trend Analysis
                    6.1. Segment Dashboard
                    6.2. U.S. Cell And Gene Therapy CDMO Market Indication Movement Analysis
                    6.3. U.S. Cell And Gene Therapy CDMO Market Size & Trend Analysis, by Indication, 2021 to 2033 (USD Million)
                    6.4. Oncology
                        6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    6.5. Infectious Diseases
                        6.5.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    6.6. Neurological disorders
                        6.6.1. Neurological disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    6.7. Rare Diseases
                        6.7.1. Rare Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    6.8. Others
                        6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
                    7.1. Company Categorization
                    7.2. U.S. Cell And Gene Therapy CDMO Market Share Analysis, 2024
                    7.3. Company Profiles
                        7.3.1. Lonza
                            7.3.1.1. Company overview
                            7.3.1.2. Financial performance
                            7.3.1.3. Product benchmarking
                            7.3.1.4. Strategic initiatives
                        7.3.2. Catalent, Inc.
                            7.3.2.1. Company overview
                            7.3.2.2. Financial performance
                            7.3.2.3. Product benchmarking
                            7.3.2.4. Strategic initiatives
                        7.3.3. Cytiva
                            7.3.3.1. Company overview
                            7.3.3.2. Financial performance
                            7.3.3.3. Product benchmarking
                            7.3.3.4. Strategic initiatives
                        7.3.4. Samsung Biologics
                            7.3.4.1. Company overview
                            7.3.4.2. Financial performance
                            7.3.4.3. Product benchmarking
                            7.3.4.4. Strategic initiatives
                        7.3.5. Thermo Fisher Scientific Inc.
                            7.3.5.1. Company overview
                            7.3.5.2. Financial performance
                            7.3.5.3. Product benchmarking
                            7.3.5.4. Strategic initiatives
                        7.3.6. Novartis AG
                            7.3.6.1. Company overview
                            7.3.6.2. Financial performance
                            7.3.6.3. Product benchmarking
                            7.3.6.4. Strategic initiatives
                        7.3.7. WuXi AppTec
                            7.3.7.1. Company overview
                            7.3.7.2. Financial performance
                            7.3.7.3. Product benchmarking
                            7.3.7.4. Strategic initiatives
                        7.3.8. AGC Biologics
                            7.3.8.1. Company overview
                            7.3.8.2. Financial performance
                            7.3.8.3. Product benchmarking
                            7.3.8.4. Strategic initiatives
                        7.3.9. OmniaBio
                            7.3.9.1. Company overview
                            7.3.9.2. Financial performance
                            7.3.9.3. Product benchmarking
                            7.3.9.4. Strategic initiatives
                        7.3.10. Rentschler Biopharma SE
                            7.3.10.1. Company overview
                            7.3.10.2. Financial performance
                            7.3.10.3. Product benchmarking
                            7.3.10.4. Strategic initiatives
                        7.3.11. Charles River Laboratories
                            7.3.11.1. Company overview
                            7.3.11.2. Financial performance
                            7.3.11.3. Product benchmarking
                            7.3.11.4. Strategic initiatives

List of Tables

Table 1 List of abbreviation
Table 2 U.S. Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 3 U.S. Cell And Gene Therapy CDMO Market estimates and forecasts, by product, 2021 - 2033 (USD Million)
Table 4 U.S. Cell And Gene Therapy CDMO Market estimates and forecasts, by indication, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 U.S. Cell And Gene Therapy CDMO Market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Value-Chain-Based Sizing & Forecasting
Fig. 9 QFD model sizing & forecasting
Fig. 10 Bottom-up approach
Fig. 11 Market snapshot
Fig. 12 Segment snapshot
Fig. 13 Segment snapshot
Fig. 14 Segment snapshot
Fig. 15 Competitive landscape snapshot
Fig. 16 Parent market outlook, 2024 (USD Million)
Fig. 17 Ancillary market outlook, 2024 (USD Million)
Fig. 18 U.S. Cell And Gene Therapy CDMO Market dynamics
Fig. 19 Total R&D drug pipeline size, 2021 - 2024
Fig. 20 Total drug pipeline by development phase, 2024
Fig. 21 Porter’s five forces analysis
Fig. 22 PESTEL analysis
Fig. 23 U.S. Cell And Gene Therapy CDMO Market Phase outlook: Segment dashboard
Fig. 24 U.S. Cell And Gene Therapy CDMO Market, by Phase segment: Market share, 2025 & 2033
Fig. 25 Pre-clinical market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 26 Clinical market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 27 U.S. Cell And Gene Therapy CDMO Market Product outlook: Segment dashboard
Fig. 28 U.S. Cell And Gene Therapy CDMO Market, by Product segment: Market share, 2025 & 2033
Fig. 29 Gene Therapy market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 30 Ex-vivo market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 31 In-vivo market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 32 Gene-Modified Cell Therapy market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 33 CAR T-cell therapies market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 34 CAR-NK cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 35 TCR-T cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 36 Cell Therapy market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 37 U.S. Cell And Gene Therapy CDMO Market Indication outlook: Segment dashboard
Fig. 38 U.S. Cell And Gene Therapy CDMO Market, by Indication segment: Market share, 2025 & 2033
Fig. 39 Oncology market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 40 Infectious Diseases market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 41 Neurological disorders market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 42 Rare Diseases market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 43 Others market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 44 Market participant categorization
Fig. 45 Heat map analysis